{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:43:16Z","timestamp":1776058996150,"version":"3.50.1"},"reference-count":221,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Lung cancer remains a leading cause of global cancer deaths, underscoring the urgent need for more accurate diagnostic and treatment approaches. Radionuclide theranostics has rapidly emerged as a paradigm that couples molecular imaging with targeted internal irradiation, enabling personalized cancer care. This review provides a systematic overview of radionuclide theranostics in lung cancer. We first summarize core theranostic principles, including the classes of diagnostic and therapeutic radionuclides and their mechanisms of action. We then emphasize target selection, discussing key molecular targets overexpressed in lung tumors and within the tumor microenvironment that are suitable for radiopharmaceutical development. We synthesize clinical translational evidence by collating efficacy and safety outcomes from pivotal studies and highlighting candidate agents currently in clinical trials. We also examine patient stratification, combination strategies, and the management of treatment-related toxicities. Finally, we outline major challenges, such as target heterogeneity, uncertainties in optimal dosing, and incomplete toxicity profiling, and propose future directions to optimize ligand design, expand target and radionuclide repertoires, and integrate radionuclide therapy with other treatment modalities.<\/jats:p>","DOI":"10.3389\/fonc.2026.1782938","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:47:38Z","timestamp":1776055658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Radionuclide theranostics: advances and clinical applications in lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]},{"name":"Institute of Surgery, Graduate School, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShengJie","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HaiYang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HaiYang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]},{"name":"Institute of Surgery, Graduate School, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YunLong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]},{"name":"Institute of Surgery, Graduate School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ChengKuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]},{"name":"Department of Thoracic Surgery, Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YiXin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Yongchuan Hospital, Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Physical Examination, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HaiNing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]},{"name":"Institute of Surgery, Graduate School, North Sichuan Medical College","place":["Nanchong, China"]},{"name":"Institute of Surgery, Graduate School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Department of Thoracic Surgery, Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","article-title":"Epidemiology of lung cancer","volume":"25","author":"Thandra","year":"2021","journal-title":"Contemp Oncol (Pozn)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052049","article-title":"Lung cancer\u2014epidemiology, pathogenesis, treatment and molecular aspect (review of literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"IJMS"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2174\/1874471013666191223151402","article-title":"Alternative and new radiopharmaceutical agents for lung cancer","volume":"13","author":"Telo","year":"2020","journal-title":"Curr Radiopharm"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.10.008","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer","volume":"11","author":"Nicholson","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: Impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152549","article-title":"Recent advances in PET and radioligand therapy for lung cancer: FDG and FAP","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.17.18264","article-title":"Targeted radionuclide therapy: An evolution toward precision cancer treatment","volume":"209","author":"Jadvar","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-024-00702-4","article-title":"Advances in radioligand theranostics in oncology","volume":"28","author":"Lawal","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.220157","article-title":"A review of theranostics: Perspectives on emerging approaches and clinical advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol Imaging Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21768","article-title":"Radiotheranostics in oncology: Making precision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA: A Cancer J For Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c20602","article-title":"Advances in preclinical research of theranostic radiopharmaceuticals in nuclear medicine","volume":"17","author":"Hu","year":"2025","journal-title":"ACS Appl Mater Interfaces"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101292","article-title":"177Lu]Lu-PSMA-617 (PluvictoTM): The first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00427","article-title":"Effective treatment of SSTR2-positive small cell lung cancer using 211At-containing targeted \u03b1-particle therapy agent which promotes endogenous antitumor immune response","volume":"20","author":"Qin","year":"2023","journal-title":"Mol Pharm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70013","article-title":"Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors","volume":"37","author":"Santo","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06048-5","article-title":"177Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases","volume":"50","author":"Rao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.icrp.2008.10.004","article-title":"ICRP publication 107. Nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann ICRP"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010033","article-title":"Targeted radionuclide therapy of human tumors","volume":"17","author":"Gudkov","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3043838","article-title":"Targeted radionuclide therapy","volume":"3","author":"Ersahin","year":"2011","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06174-8","article-title":"Radionuclide-based theranostics \u2014 a promising strategy for lung cancer","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/thno.19782","article-title":"Quantitative imaging for targeted radionuclide therapy dosimetry - technical review","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15111387","article-title":"Design and evaluation of a portable pinhole SPECT system for 177Lu imaging: Monte Carlo simulations and experimental study","volume":"15","author":"Savvidis","year":"2025","journal-title":"Diagnostics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00411-007-0116-1","article-title":"Demonstration of a radiation-induced bystander effect for low dose low LET beta-particles","volume":"46","author":"Persaud","year":"2007","journal-title":"Radiat Environ Biophys"},{"key":"B25","first-page":"4S","article-title":"Radiobiologic principles in radionuclide therapy","author":"Kassis","year":"2005","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2019.11.002","article-title":"Dosimetry, radiobiology and synthetic lethality: Radiopharmaceutical therapy (RPT) with alpha-particle-emitters","volume":"50","author":"Sgouros","year":"2020","journal-title":"Semin Nucl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165231","article-title":"Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges","volume":"27","author":"Salih","year":"2022","journal-title":"Molecules"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153676","article-title":"Targeted alpha-particle radiotherapy and immune checkpoint inhibitors induces cooperative inhibition on tumor growth of Malignant melanoma","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7150\/thno.124671","article-title":"Contemporary opportunities and potential of auger electron-emitting theranostics","volume":"16","author":"Lee","year":"2026","journal-title":"Theranostics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy - a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05475-0","article-title":"State-of-the-art of FAPI-PET imaging: A systematic review and meta-analysis","volume":"48","author":"Sollini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225566","article-title":"Performance and prospects of [68Ga]Ga-FAPI PET\/CT scans in lung cancer","volume":"14","author":"Borgonje","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: Interim analysis of a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","journal-title":"J Nucl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05638-z","article-title":"18F]AlF-NOTA-FAPI-04 PET\/CT uptake in metastatic lesions on PET\/CT imaging might distinguish different pathological types of lung cancer","volume":"49","author":"Wei","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05754-4","article-title":"Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology","volume":"49","author":"Chen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.211424","article-title":"Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in the evaluation of advanced lung cancer","volume":"303","author":"Wang","year":"2022","journal-title":"Radiology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04346-z","article-title":"FAPI-PET\/CT improves staging in a lung cancer patient with cerebral metastasis","volume":"46","author":"Giesel","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266806","article-title":"68Ga-FAPI-04 PET\/CT in non\u2013small cell lung cancer: Accurate evaluation of lymph node metastasis and correlation with fibroblast activation protein expression","volume":"65","author":"Li","year":"2024","journal-title":"J Nucl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-021-02601-1","article-title":"Mediastinum-type lung cancer on 68Ga-FAPI PET\/CT with cardiac insufficiency as the first symptom","volume":"29","author":"Liu","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1967\/s002449912724","article-title":"A comparative review of the application value of FAPI PET\/CT and 18F-FDG PET\/CT in lung cancer","volume":"27","author":"Tang","year":"2024","journal-title":"Hell J Nucl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011192","article-title":"Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [18F]F-FDG in oncology: A systematic review","volume":"22","author":"Treglia","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05700-4","article-title":"Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET\/CT in recurrent soft tissue sarcoma","volume":"49","author":"Gu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05522-w","article-title":"The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG","volume":"49","author":"Lan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05441-w","article-title":"Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: A bicentric retrospective study","volume":"49","author":"Jiang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.6058\/jlc.2011.10.2.69","article-title":"Somatostatin receptors in lung cancer: From function to molecular imaging and therapeutics","volume":"10","author":"Callison","year":"2011","journal-title":"J Lung Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1148\/radiographics.19.3.g99ma11707","article-title":"Thoracic carcinoids: Radiologic-pathologic correlation","volume":"19","author":"Rosado de Christenson","year":"1999","journal-title":"Radiographics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318279f0f5","article-title":"FDG-PET imaging in patients with pulmonary carcinoid tumor","volume":"38","author":"Moore","year":"2013","journal-title":"Clin Nucl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: A systematic review and meta-analysis","volume":"57","author":"Deppen","year":"2016","journal-title":"J Nucl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7150\/thno.98819","article-title":"Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with immunohistochemistry and survival","volume":"14","author":"Mavroeidi","year":"2024","journal-title":"Theranostics"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2011.0010","article-title":"Evaluation of the role of [18F]FDG-PET\/CT and [68Ga]DOTATOC-PET\/CT in differentiating typical and atypical pulmonary carcinoids","volume":"11","author":"Jindal","year":"2011","journal-title":"Cancer Imaging"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081837","article-title":"PSMA-directed theranostics in prostate cancer","volume":"13","author":"Jajja","year":"2025","journal-title":"Biomedicines"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.598377","article-title":"Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-\u03baB signaling pathway","volume":"9","author":"Gao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186280","article-title":"Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer","volume":"12","author":"Schmidt","year":"2017","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203570","article-title":"Imaging of nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the field, and a call to arms","volume":"59","author":"Salas Fragomeni","year":"2018","journal-title":"J Nucl Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12890-023-02377-9","article-title":"Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET\/CT in lung cancer and lymph node metastasis","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002870","article-title":"68Ga-PMSA uptake in the lung: Metastatic versus primary lung tumor","volume":"45","author":"Usmani","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000006061","article-title":"PSMA PET\/CT for improved staging accuracy and imaging of neovascularization-associated features in primary lung cancer","volume":"50","author":"Zhao","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: Management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101616","article-title":"The clinical application of 68Ga-PSMA PET\/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer","volume":"28","author":"Pei","year":"2023","journal-title":"Transl Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002367","article-title":"Intertumoral heterogeneity of 18F-FDG and 68Ga-PSMA uptake in prostate cancer pulmonary metastases","volume":"44","author":"Perez","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-023-00798-2","article-title":"Synchronous pulmonary Malignancy detected during PSMA ligand PET\/CT for initial staging of prostate cancer: a case report","volume":"57","author":"Bunnag","year":"2023","journal-title":"Nucl Med Mol Imaging"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188790","article-title":"Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm","volume":"1877","author":"Nengroo","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04444-w","article-title":"CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment","volume":"149","author":"Bao","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-targeted theranostics in oncology","volume":"49","author":"Buck","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.7150\/thno.99025","article-title":"PET imaging of CXCR4 expression using [18F]AlF-NOTA-QHY-04 for hematologic Malignancy and solid tumors","volume":"14","author":"Cheng","year":"2024","journal-title":"Theranostics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3348\/kjr.2024.1266","article-title":"Potential of C-X-C-chemokine-receptor-type-4-directed PET\/CT using [18F]AlF-NOTA-QHY-04 in identifying molecular subtypes of small cell lung cancer","volume":"26","author":"Luo","year":"2025","journal-title":"Korean J Radiol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06059-2","article-title":"68Ga]Ga-pentixafor PET\/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: Correlation with quantitative receptors\u2019 density by immunochemistry techniques","volume":"50","author":"Watts","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-025-02093-w","article-title":"Evaluating the diagnostic utility of [68Ga]Ga-pentixafor in solid tumors: A systematic review","volume":"39","author":"Ruzzeh","year":"2025","journal-title":"Ann Nucl Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2020.03.10","article-title":"EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Transl Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8840","article-title":"A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management","volume":"10","author":"Sun","year":"2018","journal-title":"Sci Transl Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2174\/1568026622666220903142416","article-title":"In vivo PET imaging of EGFR expression: An overview of radiolabeled EGFR TKIs","volume":"22","author":"Zhu","year":"2022","journal-title":"Curr Top Med Chem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-014-0080-0","article-title":"Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET","volume":"5","author":"Abourbeh","year":"2015","journal-title":"EJNMMI Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.493","article-title":"PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer","volume":"105","author":"Memon","year":"2011","journal-title":"Br J Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: Concept, design, and applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem Rev"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263907","article-title":"Single-domain antibody theranostics on the horizon","volume":"63","author":"Wei","year":"2022","journal-title":"J Nucl Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13550-021-00854-y","article-title":"Dose escalation biodistribution, positron emission tomography\/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody","volume":"11","author":"Yang","year":"2021","journal-title":"EJNMMI Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101388","article-title":"Anti-human PD-L1 nanobody for immuno-PET imaging: Validation of a conjugation strategy for clinical translation","volume":"10","author":"Bridoux","year":"2020","journal-title":"Biomolecules"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00062","article-title":"Immuno-PET imaging of 89Zr labeled anti-PD-L1 domain antibody","volume":"15","author":"Li","year":"2018","journal-title":"Mol Pharm"},{"key":"B82","doi-asserted-by":"publisher","first-page":"392","DOI":"10.7150\/thno.87243","article-title":"Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid Malignancies","volume":"14","author":"He","year":"2024","journal-title":"Theranostics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262473","article-title":"PD-L1 PET\/CT imaging with radiolabeled durvalumab in patients with advanced-stage non-small cell lung cancer","volume":"63","author":"Smit","year":"2022","journal-title":"J Nucl Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258384","article-title":"Synthesis and preclinical evaluation of a 68Ga-labeled adnectin, 68Ga-BMS-986192, as a PET agent for imaging PD-L1 expression","volume":"62","author":"Robu","year":"2021","journal-title":"J Nucl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122216","article-title":"Peptide-based PET quantifies target engagement of PD-L1 therapeutics","volume":"129","author":"Kumar","year":"2019","journal-title":"J Clin Invest"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J Nucl Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05876-9","article-title":"Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET","volume":"49","author":"Zhou","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0453","article-title":"First-in-human study of the biodistribution and pharmacokinetics of 89Zr-CX-072, a novel immunopet tracer based on an anti-PD-L1 probody","volume":"27","author":"Kist de Ruijter","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c01344","article-title":"Preclinical evaluation of 68Ga-labeled SL1 aptamer for c-Met targeted PET imaging","volume":"22","author":"Liu","year":"2025","journal-title":"Mol Pharmaceutics"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121663","article-title":"Visualizing the tumor microenvironment: Molecular imaging probes target extracellular matrix, vascular networks, and immunosuppressive cells","volume":"17","author":"Chan","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13550-021-00801-x","article-title":"99mTc]Tc-galacto-RGD2 integrin \u03b1v\u03b23-targeted imaging as a surrogate for molecular phenotyping in lung cancer: Real-world data","volume":"11","author":"Fu","year":"2021","journal-title":"EJNMMI Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.7150\/thno.44334","article-title":"The tumor targeting performance of anti-CD166 probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice","volume":"10","author":"Chomet","year":"2020","journal-title":"Theranostics"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07617-0","article-title":"Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: First-in-human, dose-escalation study","volume":"53","author":"Liu","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06809-4","article-title":"Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice","volume":"51","author":"Taddio","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05273-8","article-title":"153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma","volume":"48","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: A preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005168","article-title":"177 Lu-FAP-2286 therapy in a metastatic bone Malignant solitary fibrous tumor","volume":"49","author":"Yang","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265383","article-title":"Clinical evaluation of 68Ga-FAPI-RGD for imaging of fibroblast activation protein and integrin \u03b1v\u03b23 in various cancer types","volume":"64","author":"Zhao","year":"2023","journal-title":"J Nucl Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.7150\/thno.86007","article-title":"Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264544","article-title":"PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study","volume":"64","author":"Pang","year":"2023","journal-title":"J Nucl Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.244806","article-title":"The latest developments in imaging of fibroblast activation protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J Nucl Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06914-4","article-title":"Efficient \u03b1 and \u03b2- radionuclide therapy targeting fibroblast activation protein-\u03b1 in an aggressive preclinical mouse tumour model","volume":"52","author":"Ceuppens","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143595","article-title":"In-vivo somatostatin-receptor expression in small cell lung cancer as a prognostic image biomarker and therapeutic target","volume":"15","author":"\u015een","year":"2023","journal-title":"Cancers"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06844-1","article-title":"Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer","volume":"51","author":"Rauch","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B109","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.05.001","article-title":"Radioligand therapy in patients with lung neuroendocrine tumors: a systematic review on efficacy and safety","volume":"54","author":"Malandrino","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","author":"Baum","year":"2018","journal-title":"Oncotarget"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B113","article-title":"Therapeutic effect of 188Re-MAG3-depreotide on non-small cell lung cancer in vivo and in vitro","volume":"6","author":"Yu","year":"2013","journal-title":"Int J Clin Exp Path"},{"key":"B114","article-title":"Phase I\/II dose escalation trial of rhenium 188-P2045 in small cell lung cancer and other advanced neuroendocrine carcinomas as a single agent and in combination with topotecan","volume-title":"clinicaltrials.gov","year":"2019"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181bf1070","article-title":"Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog","volume":"4","author":"Edelman","year":"2009","journal-title":"J Thorac Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2018.01.023","article-title":"Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment","volume":"26","author":"Zhao","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07011-2","article-title":"Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors","volume":"52","author":"Njotu","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2353","article-title":"Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Rivera","year":"2013","journal-title":"Chest"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.07.91","article-title":"The value of cell block based on fine needle aspiration for lung cancer diagnosis","volume":"9","author":"Dong","year":"2017","journal-title":"J Thorac Dis"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0405","article-title":"Immuno-PET monitoring of lymphocytes using the CD8-specific antibody REGN5054","volume":"10","author":"Tavar\u00e9","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101295","article-title":"Nephrotoxicity after radionuclide therapies","volume":"15","author":"Parihar","year":"2021","journal-title":"Transl Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262295","article-title":"Biokinetics and dosimetry of 177Lu-pentixather","volume":"63","author":"H\u00e4nscheid","year":"2022","journal-title":"J Nucl Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2013.0057","article-title":"Yttrium-90 radioembolization of liver tumors: what do the images tell us","volume":"13","author":"Singh","year":"2014","journal-title":"Cancer Imaging"},{"key":"B125","article-title":"Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres","volume":"41","author":"Dancey","year":"2000","journal-title":"J Nucl Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2020.01.09","article-title":"Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm","volume":"11","author":"Jeyarajah","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1400131","article-title":"Therapeutic radionuclides in nuclear medicine: current and future prospects","volume":"15","author":"Yeong","year":"2014","journal-title":"J Zhejiang Univ-Sci B"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003399833","article-title":"Therapeutic radiopharmaceuticals","volume":"6","author":"Ercan","year":"2000","journal-title":"Curr Pharm Des"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105070","article-title":"\u03b2-radiating radionuclides in cancer treatment, novel insight into promising approach","volume":"160","author":"Asadian","year":"2020","journal-title":"Pharmacol Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1080\/0031302031000152892","article-title":"Extra-hepatic embolisation of Y-90 microspheres from selective internal radiation therapy (SIRT) of the liver","volume":"35","author":"Thamboo","year":"2003","journal-title":"Pathology"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082622","article-title":"Targeted palliative radionuclide therapy for metastatic bone pain","volume":"9","author":"Manafi-Farid","year":"2020","journal-title":"J Clin Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"B133","article-title":"(32)P in the treatment of myeloproliferative disorders","volume":"85","author":"Lawless","year":"2016","journal-title":"Ulster Med J"},{"key":"B134","first-page":"78","article-title":"Bone pain palliation with strontium-89 in cancer patients with bone metastases","volume":"45","author":"Giammarile","year":"2001","journal-title":"Q J Nucl Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2011.12.007","article-title":"Bystander normal human fibroblasts reduce damage response in radiation targeted cancer cells through intercellular ROS level modulation","volume":"731","author":"Widel","year":"2012","journal-title":"Mutat Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-021-00703-9","article-title":"KSNM60 in non-thyroidal radionuclide therapy: leaping into the future","volume":"55","author":"Byun","year":"2021","journal-title":"Nucl Med Mol Imaging"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.4103\/wjnm.WJNM_85_17","article-title":"188Re-HEDP therapy in the therapy of painful bone metastases","volume":"17","author":"Liepe","year":"2018","journal-title":"World J Nucl Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2024.111230","article-title":"A new evaluation of the decay data for 166Ho","volume":"207","author":"Zimmerman","year":"2024","journal-title":"Appl Radiat Isot"},{"key":"B139","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12876-018-0817-8","article-title":"Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)","volume":"18","author":"Braat","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/RLU.0000000000001904","article-title":"223Ra therapy in patients with advanced castration-resistant prostate cancer with bone metastases: lessons from daily practice","volume":"43","author":"van der Doelen","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-020-0600-z","article-title":"Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors","volume":"10","author":"B\u00e4ck","year":"2020","journal-title":"EJNMMI Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-011-0286-y","article-title":"An overview of targeted alpha therapy","volume":"33","author":"Kim","year":"2012","journal-title":"Tumour Biol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2967\/jnmt.113.131003","article-title":"Influence of positron emitters on standard \u03b3-camera imaging","volume":"42","author":"J\u00f8dal","year":"2014","journal-title":"J Nucl Med Technol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-024-02009-0","article-title":"Radiolabelled anti-PD-L1 peptide PET\/CT in predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer","volume":"39","author":"Zhou","year":"2025","journal-title":"Ann Nucl Med"},{"key":"B145","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224170","article-title":"Early phase I study of a 99mTc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT\/CT assessment of PD-L1 expression in non-small cell lung cancer","volume":"60","author":"Xing","year":"2019","journal-title":"J Nucl Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04646-4","article-title":"Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody","volume":"47","author":"Christensen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B148","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1021\/acs.bioconjchem.7b00631","article-title":"Imaging PD-L1 expression with immunopet","volume":"29","author":"Truillet","year":"2018","journal-title":"Bioconjug Chem"},{"key":"B149","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.nucmedbio.2020.05.006","article-title":"Immuno-SPECT\/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma","author":"Wen","year":"2020","journal-title":"Nucl Med Biol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.01.014","article-title":"Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)","volume":"153","author":"Takagi","year":"2021","journal-title":"Lung Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008794","article-title":"Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers","volume":"12","author":"Zhang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26040918","article-title":"Preliminary study of a 1,5-benzodiazepine-derivative labelled with indium-111 for CCK-2 receptor targeting","volume":"26","author":"Verona","year":"2021","journal-title":"Molecules"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06749-z","article-title":"Cholecystokinin-2 receptor targeting by [68Ga]Ga-DOTA-MGS5 PET\/CT in a patient with extensive disease small cell lung cancer","volume":"51","author":"Di Santo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B154","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1038\/s41598-017-01443-7","article-title":"Development and evaluation of 18F-IRS for molecular imaging mutant EGF receptors in NSCLC","volume":"7","author":"Song","year":"2017","journal-title":"Sci Rep"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2018.12.034","article-title":"Synthesis and preliminary evaluation of 18F-icotinib for EGFR-targeted PET imaging of lung cancer","volume":"27","author":"Lu","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.03.016","article-title":"Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET\/CT imaging","volume":"155","author":"van de Stadt","year":"2021","journal-title":"Lung Cancer"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.08.066","article-title":"Radiosynthesis and biological evaluation of 18F-labeled 4-anilinoquinazoline derivative (18F-FEA-Erlotinib) as a potential EGFR PET agent","volume":"28","author":"Huang","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.092874","article-title":"Molecular imaging with 11C-PD153035 PET\/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study","volume":"52","author":"Meng","year":"2011","journal-title":"J Nucl Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2016.11.020","article-title":"PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer","volume":"122","author":"van Loon","year":"2017","journal-title":"Radiother Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00823","article-title":"Immuno-PET imaging of EGFR with 64Cu-NOTA panitumumab in subcutaneous and metastatic nonsmall cell lung cancer xenografts","volume":"21","author":"Sarrami","year":"2024","journal-title":"Mol Pharm"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0363","article-title":"Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments","volume":"13","author":"Li","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.124941","article-title":"In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer","volume":"55","author":"Terwisscha van Scheltinga","year":"2014","journal-title":"J Nucl Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3672-x","article-title":"89Zr-Onartuzumab PET imaging of c-MET receptor dynamics","volume":"44","author":"Pool","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05995-3","article-title":"68Ga-EMP-100 PET\/CT-a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer","volume":"50","author":"Unterrainer","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115577","article-title":"Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor","volume":"28","author":"Lin","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04978-6","article-title":"Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer","volume":"48","author":"Cavaliere","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B167","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13550-020-00624-2","article-title":"Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer","volume":"10","author":"Gnesin","year":"2020","journal-title":"EJNMMI Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202000028","article-title":"Improving tumor-to-background contrast through hydrophilic tetrazines: The construction of 18 F-labeled PET agents targeting nonsmall cell lung carcinoma","volume":"26","author":"Feng","year":"2020","journal-title":"Chemistry"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1812-1","article-title":"Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of Malignancy of solitary pulmonary nodules","volume":"32","author":"Halley","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-0063-5","article-title":"Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET","volume":"33","author":"Dimitrakopoulou-Strauss","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B171","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00259-014-2888-2","article-title":"Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside","volume":"42","author":"Lewin","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00963","article-title":"Design, synthesis, and biological evaluation of 68Ga-DOTA-PA1 for lung cancer: A novel PET tracer for multiple somatostatin receptor imaging","volume":"15","author":"Liu","year":"2018","journal-title":"Mol Pharm"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1039\/c9nr04371c","article-title":"Multimodality imaging of naturally active melanin nanoparticles targeting somatostatin receptor subtype 2 in human small-cell lung cancer","volume":"11","author":"Xia","year":"2019","journal-title":"Nanoscale"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265664","article-title":"68Ga-SSO-120 PET for initial staging of small cell lung cancer patients: A single-center retrospective study","volume":"64","author":"Kersting","year":"2023","journal-title":"J Nucl Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00216","article-title":"ImmunoPET imaging of CD146 in murine models of intrapulmonary metastasis of non-small cell lung cancer","volume":"14","author":"England","year":"2017","journal-title":"Mol Pharm"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6677","article-title":"A nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancer","volume":"16","author":"Wang","year":"2017","journal-title":"Mol Med Rep"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263693","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-010-0466-y","article-title":"Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100","volume":"14","author":"Weiss","year":"2012","journal-title":"Mol Imaging Biol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7111","article-title":"A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts","volume":"7","author":"Azad","year":"2016","journal-title":"Oncotarget"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.166462","article-title":"PET imaging of VEGFR-2 expression in lung cancer with 64Cu-labeled ramucirumab","volume":"57","author":"Luo","year":"2016","journal-title":"J Nucl Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b01168","article-title":"Noninvasive trafficking of brentuximab vedotin and PET imaging of CD30 in lung cancer murine models","volume":"15","author":"Kang","year":"2018","journal-title":"Mol Pharm"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00298","article-title":"CD38 as a PET imaging target in lung cancer","volume":"14","author":"Ehlerding","year":"2017","journal-title":"Mol Pharm"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263511","article-title":"CD133 as a biomarker for an autoantibody-to-immunoPET paradigm for the early detection of small cell lung cancer","volume":"63","author":"Kunihiro","year":"2022","journal-title":"J Nucl Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2665","article-title":"Preclinical development and first-in-human imaging of the integrin \u03b1v\u03b26 with [18F]\u03b1v\u03b26-binding peptide in metastatic carcinoma","volume":"25","author":"Hausner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-018-1296-6","article-title":"PET\/CT imaging of NSCLC with a \u03b1v\u03b26 integrin-targeting peptide","volume":"21","author":"Flechsig","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00313","article-title":"68Ga-labeled cystine knot peptide targeting integrin \u03b1v\u03b26 for lung cancer PET imaging","volume":"19","author":"Ren","year":"2022","journal-title":"Mol Pharm"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.182824","article-title":"In vivo PET imaging of the cancer integrin \u03b1v\u03b26 using 68Ga-labeled cyclic RGD nonapeptides","volume":"58","author":"Notni","year":"2017","journal-title":"J Nucl Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.045864","article-title":"Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG","volume":"49","author":"Beer","year":"2008","journal-title":"J Nucl Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.113563","article-title":"First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination","volume":"54","author":"Wan","year":"2013","journal-title":"J Nucl Med"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.192393","article-title":"Response assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET\/CT in lung adenocarcinoma patients treated with nintedanib plus docetaxel","volume":"59","author":"Arrieta","year":"2018","journal-title":"J Nucl Med"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2014.1747","article-title":"First-in-human study demonstrating tumor-angiogenesis by PET\/CT imaging with (68)Ga-NODAGA-THERANOST, a high-affinity peptidomimetic for \u03b1v\u03b23 integrin receptor targeting","volume":"30","author":"Baum","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2013.06.006","article-title":"Imaging of bronchioloalveolar carcinoma in the mice with the \u03b1V\u03b23 integrin-targeted tracer (99m)Tc-RGD-4CK","volume":"162","author":"Liu","year":"2013","journal-title":"Transl Res"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.7150\/thno.19304","article-title":"The use of PET imaging for prognostic integrin \u03b12\u03b21 phenotyping to detect non-small cell lung cancer and monitor drug resistance responses","volume":"7","author":"Huang","year":"2017","journal-title":"Theranostics"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002680","article-title":"Evaluation of lung cancer and neuroendocrine neoplasm in a single scan by targeting both somatostatin receptor and integrin \u03b1v\u03b23","volume":"44","author":"Zheng","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3808","article-title":"131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging","volume":"50","author":"Chen","year":"2017","journal-title":"Int J Oncol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00056","article-title":"ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung cancer","volume":"14","author":"Ehlerding","year":"2017","journal-title":"Mol Pharm"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga labeling: Biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J Nucl Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967","article-title":"68 Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00299-2","article-title":"68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial","volume":"26","author":"Pabst","year":"2025","journal-title":"Lancet Oncol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.213","article-title":"89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer","volume":"33","author":"Kok","year":"2022","journal-title":"Ann Oncol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05672-x","article-title":"Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05315-1","article-title":"Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms","volume":"48","author":"Tafreshi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00703","article-title":"Evaluating 225Ac and 177Lu radioimmunoconjugates against antibody-drug conjugates for small-cell lung cancer","volume":"17","author":"Lakes","year":"2020","journal-title":"Mol Pharm"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers","volume":"25","author":"Hagemann","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.108","article-title":"Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer","volume":"23","author":"Chen","year":"2005","journal-title":"J Clin Oncol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000481","article-title":"Targeted radionuclide therapy for lung cancer with iodine-131-labeled peptide in a nude-mouse model","volume":"28","author":"Chen","year":"2017","journal-title":"Anticancer Drugs"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.16.16947","article-title":"Antitumor effect of nanoparticle 131I-labeled arginine-glycine-aspartate-bovine serum albumin-polycaprolactone in lung cancer","volume":"208","author":"Ming","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910638","article-title":"Localization and tumor growth inhibition of I-131-labeled monoclonal antibody ERIC1 in a subcutaneous xenograft model of small cell lung cancer in SCID mice","volume":"25","author":"Fischer","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B209","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/2211556009666200413085800","article-title":"Thymoquinone glucuronide conjugated magnetic nanoparticle for bimodal imaging and treatment of cancer as a novel theranostic platform","volume":"14","author":"\u0130nce","year":"2021","journal-title":"Curr Radiopharm"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4568","article-title":"Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: First-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105775","article-title":"Multimodality labeling of NGR-functionalized hyaluronan for tumor targeting and radiotherapy","volume":"161","author":"Li","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"B213","article-title":"Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: Evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I","volume":"42","author":"Stein","year":"2001","journal-title":"J Nucl Med"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06979-1","article-title":"Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy","volume":"52","author":"Zavvar","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1098","article-title":"Targeted radionuclide therapy in patient-derived xenografts using 177Lu-EB-RGD","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104100","article-title":"177Lu-labeled cyclic RGD peptide as an imaging and targeted radionuclide therapeutic agent in non-small cell lung cancer: Biological evaluation and preclinical study","volume":"102","author":"Pirooznia","year":"2020","journal-title":"Bioorg Chem"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0037","article-title":"Phase I study of P-cadherin-targeted radioimmunotherapy with 90Y-FF-21101 monoclonal antibody in solid tumors","volume":"26","author":"Subbiah","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1186-0","article-title":"In vivo therapeutic effect of CDH3\/P-cadherin-targeting radioimmunotherapy","volume":"61","author":"Yoshioka","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-00718-8","article-title":"Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice","volume":"37","author":"Chang","year":"2019","journal-title":"Invest New Drugs"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21101308","article-title":"Re-188 enhances the inhibitory effect of bevacizumab in non-small-cell lung cancer","volume":"21","author":"Xiao","year":"2016","journal-title":"Molecules"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00304","article-title":"Chemoradiotherapeutic magnetic nanoparticles for targeted treatment of nonsmall cell lung cancer","volume":"12","author":"Munaweera","year":"2015","journal-title":"Mol Pharm"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782938\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:47:48Z","timestamp":1776055668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782938\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":221,"alternative-id":["10.3389\/fonc.2026.1782938"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1782938","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1782938"}}